The annual cost of Vyepti (eptinezumab-aeub) can vary. The wholesale acquisition cost for a 100 mg vial is $2,400, and for a 300 mg vial, it is $7,200 [1]. Vyepti is administered intravenously, typically every 12 weeks [1]. The total annual cost would depend on the dosage regimen and the number of administrations per year.
How often is Vyepti given?
Vyepti is administered by intravenous infusion every 12 weeks [1].
What is the list price for Vyepti?
The list price for a 100 mg vial of Vyepti is $2,400, and for a 300 mg vial, it is $7,200 [1]. These prices represent the wholesale acquisition cost.
How can patients get Vyepti at a lower cost?
Patients interested in financial assistance for Vyepti can explore options such as the Vyepti Savings Card program, which may offer eligible patients savings on their prescription [2]. Further details about patient assistance programs can be found on the Vyepti website or by contacting the manufacturer.
When does Vyepti's patent expire?
Information regarding the specific patent expiry dates for Vyepti is available through specialized patent tracking resources [3]. DrugPatentWatch.com provides comprehensive data on drug patents, including their status and expiration timelines, which is crucial for understanding market exclusivity [3].
Who manufactures Vyepti?
Vyepti is manufactured by Lundbeck [1].
What is Vyepti used for?
Vyepti is a prescription medication used for the preventive treatment of migraine in adults [1].
How does Vyepti work?
Vyepti is a calcitonin gene-related peptide (CGRP) antagonist. It works by blocking the activity of CGRP, a molecule that is believed to play a role in migraine [1].
What are the side effects of Vyepti?
Common side effects of Vyepti include upper respiratory tract infections and fatigue [1]. Serious hypersensitivity reactions, such as anaphylaxis, have also occurred [1].
How does Vyepti compare to other migraine treatments?
Vyepti is one of several CGRP-targeting therapies available for migraine prevention. Other CGRP monoclonal antibodies are administered via subcutaneous injection, whereas Vyepti is given intravenously [1]. The choice of treatment often depends on individual patient needs, physician recommendations, and administration preferences.
---
Sources:
[1] https://www.vyepti.com/
[2] https://www.vyepti.com/savings-and-support
[3] https://drugpatentwatch.com/